The Alliance for Artificial Intelligence in Healthcare
@theaaih.bsky.social
AI drug discovery startups are moving beyond software, building their own drug pipelines to attract investors and boost revenue. But as Luka Jelcic notes, blending fast-moving AI with slow-burn biotech isn’t simple. Investors now favor companies with tangible assets over vague platform promises.
May 3, 2025 at 12:52 AM
AI drug discovery startups are moving beyond software, building their own drug pipelines to attract investors and boost revenue. But as Luka Jelcic notes, blending fast-moving AI with slow-burn biotech isn’t simple. Investors now favor companies with tangible assets over vague platform promises.
Fireside Chat: AI & Drug Development – Challenges, Disruption & the Future.
Inspired by Luka’s co-authored white paper, “Inflection Points of Artificial Intelligence in Drug Development,” this conversation dives deep into trends, challenges, & breakthroughs shaping the future of AI in biopharma.
Inspired by Luka’s co-authored white paper, “Inflection Points of Artificial Intelligence in Drug Development,” this conversation dives deep into trends, challenges, & breakthroughs shaping the future of AI in biopharma.
May 1, 2025 at 11:57 PM
Fireside Chat: AI & Drug Development – Challenges, Disruption & the Future.
Inspired by Luka’s co-authored white paper, “Inflection Points of Artificial Intelligence in Drug Development,” this conversation dives deep into trends, challenges, & breakthroughs shaping the future of AI in biopharma.
Inspired by Luka’s co-authored white paper, “Inflection Points of Artificial Intelligence in Drug Development,” this conversation dives deep into trends, challenges, & breakthroughs shaping the future of AI in biopharma.